Adjuvant Therapy for T2N0M0 Hormone-Positive, HER2-Negative Invasive Ductal Carcinoma

Introduction to Adjuvant Therapy

The National Comprehensive Cancer Network recommends adjuvant treatment with endocrine therapy for 5-10 years, with consideration of chemotherapy based on genomic risk assessment or clinical-pathologic features for patients with T2N0M0 hormone receptor-positive, HER2-negative breast cancer 1, 2

Obtain a 21-gene recurrence score (Oncotype DX) or similar multigene assay to guide chemotherapy decisions, as the magnitude of benefit from endocrine therapy depends on the recurrence score, with high scores gaining less benefit from endocrine therapy alone 2
If recurrence score is high or genomic testing unavailable with high-risk clinical features, add chemotherapy before endocrine therapy, with chemotherapy administered first, followed by sequential endocrine therapy 1, 2
If recurrence score is low and tumor has favorable features, proceed directly to endocrine therapy alone 2

For postmenopausal women, aromatase inhibitors (letrozole, anastrozole, or exemestane) are preferred over tamoxifen for 5-10 years, as letrozole demonstrated superior disease-free survival compared to tamoxifen 1
For premenopausal women, tamoxifen for 5-10 years is the standard approach, decreasing annual odds of recurrence by 41% and death by 31% regardless of chemotherapy use, age, or nodal status 1
For high-risk premenopausal patients, consider ovarian function suppression plus aromatase inhibitor 2

Preferred regimens include anthracycline-based followed by taxanes (AC→paclitaxel or docetaxel) or docetaxel-cyclophosphamide, as taxanes provide particular benefit in hormone receptor-positive disease, overcoming relative chemoresistance 1

Tumors with ER-low-positive (1-10% staining) behave more like ER-negative cancers and require individualized risk-benefit assessment for both endocrine therapy and chemotherapy, as these patients may derive limited benefit from endocrine therapy alone 1, 2
Assess menopausal status by monitoring estradiol and FSH/LH levels if under age 60 and amenorrheic for ≤12 months prior to treatment, as menopausal status cannot be determined while receiving ovarian function suppression 1

Standard duration is 5 years, with extension to 10 years for high-risk patients, weighing ongoing benefits against cumulative toxicity and quality of life considerations 1, 2